SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra advanced robotic surgical system from SS Innovations.
The company reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines. This growth underscores the increasing adoption of robotic-assisted surgery in emerging markets and highlights SS Innovations' efforts to make advanced surgical technology more accessible worldwide.
In a LinkedIn post, the company congratulated Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for their achievement, thanking them for their trust and commitment to advancing robotic cardiac surgery in the region. The post also reaffirmed SS Innovations' commitment to enabling hospitals and healthcare providers with cutting-edge robotic solutions. For more details on the company's news and updates, visit the company's newsroom at https://ibn.fm/SSII.
The expansion into cardiac surgery is significant as it demonstrates the versatility of the SSi Mantra system beyond general surgical procedures. Robotic cardiac surgery offers potential benefits such as smaller incisions, reduced pain, and faster recovery times compared to traditional open-heart surgery. By establishing this program at HCG Hospital, SS Innovations is positioning itself at the forefront of a growing trend toward minimally invasive cardiac interventions in India and beyond.
SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets. These regulatory milestones, if achieved, could open doors to some of the largest healthcare markets in the world, significantly increasing the company's addressable market and driving further installations. The company's global footprint already spans 12 countries, and the addition of FDA clearance and CE marking would likely accelerate adoption among hospitals seeking reliable, advanced robotic systems.
The launch of the robotic cardiac surgery program at HCG Hospital is a testament to SS Innovations' growing influence in the surgical robotics industry. As more hospitals adopt the SSi Mantra system, the company is well-positioned to capture a larger share of the global surgical robotics market, which is projected to grow substantially in the coming years. For investors, the company's expanding install base and regulatory progress could signal long-term growth potential.
InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, distributed the original announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers a range of services including editorial syndication to 5,000+ outlets and social media distribution. These services help companies like SS Innovations reach a wide audience of investors and industry professionals. For more information on InvestorWire's offerings, visit InvestorWire.
The advancement of robotic cardiac surgery at HCG Hospital not only benefits patients in India but also contributes to the global evolution of surgical care. As SS Innovations continues to expand its reach and pursue regulatory approvals, the company is poised to play a key role in shaping the future of robotic surgery.
